MedPath

Nusantara Diet (Low Calorie and Low Sodium) for Metabolic Syndrome

Not Applicable
Recruiting
Conditions
Metabolic Syndrome
Diabetes
Hyperlipidemias
Interventions
Behavioral: Nutrition Counseling
Dietary Supplement: Diet Nusantara
Registration Number
NCT05566197
Lead Sponsor
Hasanuddin University
Brief Summary

The goal of this randomized clinical trial is to evaluate the effect of Nusantara Diet (Low Calorie and Low Sodium) for Metabolic Syndrome. The main questions it aims to answer are:

* How effective the Nusantara diet in reducing body mass index and body fat percentage?

* How effective the Nusantara diet in affecting lipid profile and insulin resistance?

Participants will be given this diet for a period of 56 days and undergo repeated outcome measurement. This study has a comparison group (no intervention) to see the difference of reduction or slope of changes in outcomes. We assumed that the Nusantara diet will reduce the metabolic syndrome indicators (anthropometry, lipid profile, and insulin resistance profile).

Detailed Description

Design

a. Randomized controlled trial with pre-post design

Intervention :

1. Balance Nutrition with low calorie and low sodium. Low calorie means a diet with 500 kilocalories lower than the Basal Energy Expenditure, according to the Harris-Benedict formula. The daily limit of sodium is 2300 mg.

2. Organoleptic test for set menu

3. Given as a set for 56 days

4. Dietary counseling is given before intervention, followed by a 24-hour food recall every week.

Outcome

1. Body mass index

2. Blood chemistry test: Total Cholesterol, Low-Density Lipoprotein (LDL), High-density Lipoprotein, Triglyceride,

4. Glucose profile (Fasting blood glucose, and Homeostatic Model Assessment for Insulin Resistance / HOMA-IR) 3. Body Fat percentage using Bioelectrical Impedance Analyzer

Sample Size Estimation With the following assumption

1. Type I error: 5%

2. Power of Study: 80%

3. Superiority Trial

4. Equal allocation with two arms

5. Assuming that the reduction of LDL would be 30% of the average LDL level among metabolic syndrome individuals (106.4 mg/dL), the total sample would be 48 participants

Protocol Analysis

1. Intention-to-treat analysis

2. Sensitivity analysis and subgroup analysis

3. If the randomization obtains an equal baseline characteristic, an Independent T-test will be applied.

4. Regression model will be applied, adjusting any possible confounder.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Fulfill the definition of metabolic syndrome

    1. Blood Pressure>135/85 mmHg
    2. Central obesity with waist circumference for males>90 cm or >80 cm in females
    3. Triglyceride level >150 mg/dL, followed by HDL<40 mg/dL
    4. blood fasting glucose >100 mg/dL
Exclusion Criteria
  1. pregnant or breastfeeding women
  2. suffer from chronic disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ControlNutrition CounselingThis group will receive standard diet and nutrition counseling.
InterventionNutrition CounselingThis group will receive dietary adjustment and nutrition counseling.
InterventionDiet NusantaraThis group will receive dietary adjustment and nutrition counseling.
Primary Outcome Measures
NameTimeMethod
Body Mass Indexchanges of body mass index from baseline to day 56

Defined as body weight in kilogram defined by square of body height in meter. Higher number indicates obesity

Lipid profilechanges of lipid profile from baseline to day 56

parameters of lipid (total cholesterol, LDL, HDL, Triglyceride) measured from blood sample

Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)changes of HOMA-IR from baseline to day 56

HOMA-IR was calculated according to the formula: fasting insulin x fasting glucose/22.5.

Body Fat Percentagechanges of Body Fat Percentage from baseline to day 56

Body Fat Percentage is the total mass of fat divided by total body mass, multiplied by 100. This is measured by Bioelectrical Impedance Analyzer.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Wahidin Sudirohusodo General Hospital

🇮🇩

Makassar, South Sulawesi, Indonesia

© Copyright 2025. All Rights Reserved by MedPath